Press Room

2016 CPhI Worldwide

Start
Tuesday, October 04, 2016 - 00:00
End
Thursday, October 06, 2016 - 00:00
Location: Barcelona, Spain
Booth Number: 3F40

Hovione will be attending CPhI Worldwide 2016 in Barcelona, Spain. An event that is considered the world's leading European pharmaceutical exhibition, which brings together more than 36,000 pharma industry professionals from 150+ countries.

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

We look forward to meeting you at our booth # 3F40 in Barcelona.

 

HOVIONE SPEAKERS

 

Mon, Oct 3, 3:45 PM - Theatre One

CPhI's Pre-Connect Congress

Panel discussion: Special Drug Designations

Moderator: Cynthia Challener, Scientific Content Director, That’s Nice LLC

 

guy villax portrait photo Hovione

Guy Villax

Non-Executive Board Member

Degree in Accounting and Financial Management

Guy Villax has a degree in Management from the University College at Buckingham, UK.

Guy Villax was Hovione's Chief Executive from 1997 to 2022, having previously worked at Price Waterhouse in London and Hovione in Asia.

Guy holds leadership positions at industry associations and in Portuguese state organizations: Rx-360, Health Cluster Portugal, Portugal’s Business Roundtable; and the ANI (Portugal’s National Innovation Agency) and the CNCTI (National Council for Science, Technology and Innovation).

Wed, Oct 5, 3:30 PM - Theatre One

CPhI's Pharma Insight Briefings

Panel discussion: Beyond APIs: The Move into Formulation Services

Moderator: Rick Mullin, Senior Editor, American Chemical Society

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026